These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 12519740)

  • 21. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
    Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
    Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of antituberculosis drugs expressed in defined daily doses in Klenovnik Hospital in the period between 1983 and 1987.
    Trkanjec Z; Tekavec J
    Tuber Lung Dis; 1993 Feb; 74(1):16-9. PubMed ID: 8495013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of short-term effects of short-course intermittent chemotherapies of the World Bank Loaned Project].
    Wen S; Su Y; Zhang F
    Zhonghua Jie He He Hu Xi Za Zhi; 1996 Dec; 19(6):357-9. PubMed ID: 9596819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

  • 25. Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
    Snider DE; Zierski M; Graczyk J; Bek E; Farer LS
    Eur J Respir Dis; 1986 Jan; 68(1):12-8. PubMed ID: 3512281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
    Small PM; Schecter GF; Goodman PC; Sande MA; Chaisson RE; Hopewell PC
    N Engl J Med; 1991 Jan; 324(5):289-94. PubMed ID: 1898769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Short-course treatment of pulmonary tuberculosis: comparison with a classical standard regimen].
    Bouslama A; Hedhiri H; Marzouki M; Jerray M; Djenayah F
    Bull Int Union Tuberc; 1985; 60(1-2):29-30. PubMed ID: 4074969
    [No Abstract]   [Full Text] [Related]  

  • 28. Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?
    Long R; Scalcini M
    Int J Tuberc Lung Dis; 1999 Sep; 3(9):747-8. PubMed ID: 10488879
    [No Abstract]   [Full Text] [Related]  

  • 29. [Short term chemotherapy of tuberculosis. Evaluation of an 18-week-long treatment including pyrazinamide (preliminary results)].
    Pretet S; Grosset J; Perdrizet S
    Bull Int Union Tuberc; 1978 Dec; 53(4):260-1. PubMed ID: 387140
    [No Abstract]   [Full Text] [Related]  

  • 30. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
    Nuermberger E; Rosenthal I; Tyagi S; Williams KN; Almeida D; Peloquin CA; Bishai WR; Grosset JH
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2621-5. PubMed ID: 16870750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
    Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intermittent chemotherapy of pulmonary tuberculosis (review of the literature)].
    Utkin VV
    Probl Tuberk; 1978 Oct; (10):23-8. PubMed ID: 714901
    [No Abstract]   [Full Text] [Related]  

  • 36. Sputum-smear-negative pulmonary tuberculosis: controlled trial of 3-month and 2-month regimens of chemotherapy.
    Lancet; 1979 Jun; 1(8131):1361-3. PubMed ID: 87829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
    Mitchison DA; Nunn AJ
    Am Rev Respir Dis; 1986 Mar; 133(3):423-30. PubMed ID: 2420242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intensive chemotherapy of pulmonary tuberculosis].
    Shesterina MV; Gavrilenko VS; Tarasova EF; Sokolova GV; Tregubov IuG
    Probl Tuberk; 1980 Jul; (7):20-22. PubMed ID: 6997865
    [No Abstract]   [Full Text] [Related]  

  • 40. Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis.
    Kumar L; Gupta R; Puri MM; Jaiswal A; Srinath ; Murar A; Behera D
    J Assoc Physicians India; 2011 Nov; 59():733-5. PubMed ID: 22616343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.